Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.
Acetaminophen (APAP) overdose is the most common cause of acute liver failure in the West. In mice, APAP hepatotoxicity can be rapidly induced with a single dose. Because it is both clinically relevant and experimentally convenient, APAP intoxication has become a popular model of liver injury. Early data demonstrated that rats are resistant to APAP toxicity. As a result, mice are the preferred species for mechanistic studies. Furthermore, recent work has shown that the mechanisms of APAP toxicity in humans are similar to mice. Nevertheless, some investigators still use rats. New mechanistic information from the last forty years invites a reevaluation of the differences between these species. Comparison may provide interesting insights and confirm or exclude the rat as an option for APAP studies. To this end, we treated rats and mice with APAP and measured parameters of liver injury, APAP metabolism, oxidative stress, and activation of the c-Jun N-terminal kinase (JNK). Consistent with earlier data, we found that rats were highly resistant to APAP toxicity. Although overall APAP metabolism was similar in both species, mitochondrial protein adducts were significantly lower in rats. Accordingly, rats also had less oxidative stress. Finally, while mice showed extensive activation and mitochondrial translocation of JNK, this could not be detected in rat livers. These data support the hypothesis that mitochondrial dysfunction is critical for the development of necrosis after APAP treatment. Because mitochondrial damage also occurs in humans, rats are not a clinically relevant species for studies of APAP hepatotoxicity.
对乙酰氨基酚(APAP)过量是西方急性肝衰竭最常见的原因。在小鼠中,单次剂量即可迅速诱导 APAP 肝毒性。由于其具有临床相关性和实验便利性,APAP 中毒已成为肝损伤的常用模型。早期数据表明,大鼠对 APAP 毒性具有抗性。因此,小鼠成为研究机制的首选物种。此外,最近的研究表明,人类的 APAP 毒性机制与小鼠相似。尽管如此,一些研究人员仍在使用大鼠。过去四十年的新机制信息促使我们重新评估这些物种之间的差异。比较可能会提供有趣的见解,并确认或排除大鼠作为 APAP 研究的选择。为此,我们用 APAP 处理大鼠和小鼠,并测量肝损伤、APAP 代谢、氧化应激和 c-Jun N-末端激酶(JNK)激活的参数。与早期数据一致,我们发现大鼠对 APAP 毒性具有高度抗性。尽管两种物种的整体 APAP 代谢相似,但大鼠的线粒体蛋白加合物明显较低。相应地,大鼠的氧化应激也较少。最后,虽然小鼠显示 JNK 广泛激活和线粒体易位,但在大鼠肝脏中无法检测到。这些数据支持线粒体功能障碍对于 APAP 治疗后发生坏死的发展至关重要的假设。由于线粒体损伤也发生在人类中,因此大鼠不是研究 APAP 肝毒性的临床相关物种。